Long-Term Effects of Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 3- and 6-Year Results of the ADJUVITE Trial
Adalimumab was effective in maintaining long-term uveitis control in patients with JIA-U, with a good safety profile. However, complete discontinuation was not possible in most cases, confirming the suspending effect of adalimumab.
Authors
- Yoo-Ri Chung (ORCID: https://orcid.org/0000-0002-6871-6721)
- Sara Touhami (ORCID: https://orcid.org/0000-0001-8346-3067)
- Isabelle J. Marié (ORCID: https://orcid.org/0000-0002-3091-7624)
- Phuc LeHoang (ORCID: https://orcid.org/0000-0003-4722-1831)
- F. Mouriaux
- Isabelle Koné‐Paut (ORCID: https://orcid.org/0000-0001-8939-5763)
- A. Mainguy (ORCID: https://orcid.org/0000-0003-0871-7834)
- C. Couret (ORCID: https://orcid.org/0000-0001-5327-6850)
- Christine Fardeau (ORCID: https://orcid.org/0000-0003-1935-2711)
- Delphine Lam
- Pierre Quartier (ORCID: https://orcid.org/0000-0002-1769-549X)
- Bahram Bodaghi (ORCID: https://orcid.org/0000-0002-0962-5301)
- V. Despert
- Michel Weber (ORCID: https://orcid.org/0000-0002-2346-6618)
Institutions
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Hôpital Tenon (FR)
- Université d'Angers (FR)
- Ajou University (KR)
- Nantes Université (FR)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1080/09273948.2025.2495826
- Citations
- 1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 1.71